Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Amortizatization of Intangibles (2024 - 2025)

Historic Amortizatization of Intangibles for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $383000.0.

  • Prelude Therapeutics' Amortizatization of Intangibles fell 5300.61% to $383000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $4.6 million for FY2024, which is 3357.33% up from last year.
  • Prelude Therapeutics' Amortizatization of Intangibles amounted to $383000.0 in Q3 2025, which was down 5300.61% from $383000.0 recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Amortizatization of Intangibles registered a high of $1.5 million during Q1 2024, and its lowest value of $383000.0 during Q2 2025.